

## Special Issue

# Skin Cancer: Imaging and Radiotherapy

### Message from the Guest Editor

We are pleased to announce a Special Issue focused on imaging technology and radiotherapy. Skin cancer is the most common human cancer. Over the past four decades, due to the development of imaging, the diagnostic accuracy of non-melanocytic and melanocytic skin cancers has been enhanced. More and more new devices and technologies are beginning to appear, and advances in cancer diagnosis have greatly improved patients' survival chances. Additionally, advancements in medical imaging have been critical to the evolution of modern radiotherapy. Radiation therapy is an essential treatment option for cancer treatment and one of the most effective therapies to cure cancer, especially for non-melanoma skin cancer. It also can be delivered in combination with other treatments, which further increases the cure rate for radiation-treated patients. We eagerly anticipate receiving your valuable contributions to this Special Issue. Your expertise and insights will undoubtedly enrich the content and impact of this publication. We look forward to your participation.

---

### Guest Editor

Dr. Fabio Sandomenico

Radiology Unit, Buon Consiglio Fatebenefratelli Hospital, 80123 Naples, Italy

---

### Deadline for manuscript submissions

closed (31 May 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/180932](https://mdpi.com/si/180932)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)